Merck & Company, Inc.
No mega hedge funds in our coverage currently report a major 13F position in this stock for 2026 Q3
Coverage: 0.0%
-
💡 Methodology: Share changes > ±0.5% are classified as Buys/Sells; changes within ±0.5% are Unchanged. Net Buying Ratio = (Buy + New) / Total Holding Funds.
Based on 2026 Q3 SEC 13F filings
🚀MRK SGDC Quant Rating & Setup
📌 Business Moat Summary:Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
As of 2026-11-18 close, trading below 50SMA support (settlement price $137.78 < $145.67), triggering momentum risk gate.
📈8-Quarter Institutional Ownership Evolution
Historical trajectory of institutional holders and allocation weight across the last 8 quarters
🏛️Institutional Investors Holding this Stock2026 Q3
Examine each hedge fund holding this ticker in 2026 Q3, weight, shares, and action
| Manager / Fund | Fund AUM | Weight | Shares Held | Action | Action |
|---|---|---|---|---|---|
| No tracked mega hedge funds currently hold this stock. | |||||
Want to see Wall Street's Top 50 Consensus Buys?
Instead of checking individual stocks, get the complete list of high-conviction overlap picks across 33 hedge funds.
⚡Planning to trade MRK?
Add this symbol to your private journal or dividend tracker to monitor institutional moves.